This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Feb 19, 2020
by Zacks Equity Research
Companies In The News Are:
Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
by Zacks Equity Research
It was a low-key week for the biotech sector with updates from just a few small biotech companies.
Moving Average Crossover Alert: Bellerophon Therapeutics (BLPH)
by Zacks Equity Research
Bellerophon Therapeutics, Inc. (BLPH) could be a stock to avoid from a technical perspective
5 Biotech Stocks Under $10 Worthy of Investors' Attention
by Indrajit Bandyopadhyay
Small biotech stocks are good bets with lower market cap as well as share price.
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp
Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate
by Swarup Gupta
With trade-related tensions refusing to die down, small-cap stocks are looking like an increasingly attractive proposition.
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
by Zacks Equity Research
Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.
Pick 3 Biotech Money-Spinning Bets Amid Market Instability
by Debapriya Chakraborty
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.
Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Bellerophon Therapeutics, Inc. (BLPH).